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Summary: Men and women in South Africa and men who have sex with men remain at 
increased risk of developing Kaposi sarcoma compared with other HIV-positive persons who 
initiated antiretroviral therapy, likely due to high human herpesvirus 8 coinfection rates. 
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Abstract (word count: 250) 
Background: We compared Kaposi sarcoma (KS) risk in adults who initiated antiretroviral 
therapy (ART) across the Asia-Pacific, South Africa, Europe, Latin, and North America. 
Methods: We included cohort data of HIV-positive adults who initiated ART after 1995 within 
the framework of two large collaborations of observational HIV cohorts. We present 
incidence rates and adjusted hazard ratios (aHRs). 
Results: We included 208,140 patients from 57 countries. Over 1,066,572 person-years (pys) 
2,046 KS cases were diagnosed. KS incidence rates per 100,000 pys were 52 in the Asia-Pacific, 
and ranged between 180 and 280 in the other regions. KS risk was five times higher in South 
African women (aHR 4.56, 95% confidence intervals [CI] 2.73-7.62) and two times higher in 
South African men (aHR 2.21, 95% CI 1.34-3.63) compared to their European counterparts. In 
Europe, Latin, and North America KS risk was six times higher in men who have sex with men 
(MSM, aHR 5.95, 95% CI 5.09-6.96) than in women. Comparing patients with current CD4 cell 
counts ≥700 cells/µl to those with CD4 counts <50 cells/µl, KS risk was halved in South Africa 
(aHR 0.53, 95% CI 0.17-1.63), but reduced by ≥95% in other regions.  
Conclusions: Despite important ART-related declines in KS incidence, men and women in 
South Africa and MSM remain at increased KS risk, likely due to high human herpesvirus 8 
coinfection rates. Early ART initiation and maintaining high CD4 cell counts are essential to 
further reduce KS incidence worldwide, but especially in Southern Africa additional measures 
might be needed.  
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Introduction 
People infected with human immunodeficiency virus (HIV) are at high risk of developing 
Kaposi sarcoma (KS) [1], and this risk appears to vary geographically. KS incidence rates seem 
to be higher in adults who initiated antiretroviral therapy (ART) in sub-Saharan Africa [2,3] 
and the US [4] than in Europe [5]. However, direct comparisons of KS incidence rates across 
studies are complicated by differences in study populations and designs.  
Several factors could contribute to regional differences in KS risk, including differences in the 
HIV epidemic, the adequacy of local health care, and the prevalence of human herpesvirus 8 
(HHV-8). HHV-8 is a necessary but not sufficient cause of KS [6], and its distribution varies by 
geographic region and population group [7]. HIV-related immunosuppression is a strong risk 
factor for KS in HHV-8 coinfected persons [5,8–10]. Access to health care varies across regions, 
and patients in high-income countries initiate ART at higher CD4 cell counts than patients in 
low- and middle-income settings [11]. 
We compared KS incidence rates in HIV-positive adults who initiated ART across different 
continents, and assessed factors associated with regional differences in KS risk.  
 
Methods 
Databases 
We analyzed longitudinal routine clinical care data of HIV-positive patients within the 
framework of the International epidemiology Databases to Evaluate AIDS (IeDEA) and the 
Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in 
EuroCoord. IeDEA is a global research consortium of observational HIV cohorts with data 
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centers in the Asia-Pacific, Australia, Africa, North, and Latin America. Four IeDEA regions 
contributed data to this study: the North American AIDS Cohort Collaboration on Research 
and Design (NA-ACCORD) [12], the Caribbean, Central and South America network for HIV 
epidemiology (CCASAnet) [13], IeDEA Southern Africa [14], and IeDEA Asia-Pacific[15]; the 
latter includes data from two geographical regions: the Asia-Pacific and Australia. COHERE in 
EuroCoord is a collaboration of observational HIV cohorts across Europe [16]. For details on 
how data were collected and combined, see Supplementary box S1. All cohorts obtained 
ethical approval from local ethics committees or institutional review boards. 
Inclusion criteria and definitions 
We restricted the analysis to cohorts that systematically collected cancer data or had 
improved their data through record linkages with cancer registries. We included HIV-positive 
adults (≥16 years) who initiated ART after enrolment into cohort from 1996 onward. We 
excluded patients without follow-up after ART initiation, and patients with no CD4 
measurements under follow-up. We excluded regions with <500 eligible patients and cohorts 
with <100 eligible patients. We excluded the region Asia-Pacific from statistical models due 
to few KS cases (post-hoc decision). Incident KS cases were defined as histologically or 
clinically diagnosed KS at any time after ART initiation. ART was defined as a regimen of at 
least three antiretroviral drugs from any class, including protease inhibitors (PIs), nucleoside 
reverse transcriptase inhibitors, and non-nucleoside reverse transcriptase inhibitors 
(NNRTIs). Patients were assumed to remain on ART once initiated. CD4 counts at ART 
initiation were defined as the measurement nearest to ART initiation within 180 days before 
to seven days after initiation. The HIV/AIDS stage at ART initiation was defined according to 
the US Centers for Disease Control and Prevention (CDC) [17]. 
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Statistical analyses 
We calculated raw KS incidence rates by dividing the number of incident KS cases by person-
years (pys) at risk. Time at risk was measured from ART initiation to the first occurrence of KS 
diagnosis, last follow-up visit, death, or database closure. We anticipated that the KS hazard 
would vary by follow-up time and geographic region and used proportional hazard flexible 
parametric survival models [18] to compare the risk of developing KS after ART initiation 
across regions and to identify KS risk factors. We modeled the baseline hazard using restricted 
cubic splines with four degrees of freedom and allowed for time-dependent region-effects 
with two degrees of freedom. Likelihood ratio tests were used to test for interactions 
between risk factors and regions. We assessed gender, exposure group (women, heterosexual 
men, MSM), age at ART initiation (16-25, 26-35, 36-45, 46-55, ≥56 years), first-line ART 
regimen (NNRTI-based, PI-based, other), calendar period of ART initiation (1996-1998, 1999-
2003, 2004-2007, 2008-2014), and current (time-updated) CD4 cell count (<50, 50-99, 100-
199, 200-349, 350-499, 500-699, ≥700 cells/µl). Mode of infection, HIV/AIDS stage, and HIV 
RNA at ART initiation were assessed in descriptive analyses.  
We fit “crude” models with one risk factor and its interaction with region (where applicable) 
to compare the actual KS burden across regions. Adjusted models with relevant risk factors 
and their interaction with region (if necessary) were then fit to assess remaining differences 
in KS incidence rates across regions. The main adjusted model included region, gender and its 
interaction with region, age at ART initiation and its interaction with region, current CD4 count 
and its interaction with region, first-line ART regimen, and calendar period of ART initiation. 
The second adjusted model was restricted to the three regions with data on sexual 
orientation, Europe, Latin, and North America, and included exposure group, age at ART 
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initiation, current CD4 cell count, first-line ART regimen, and calendar period of ART initiation. 
In sensitivity analyses, we excluded the first three months of follow-up. KS incidence rates 
were predicted from adjusted models for patients with a standardized risk factors set: 
initiation of NNRTI-based regimens between 2008-2014 at the age of 40 years and current 
CD4 cell count between 350-499 cells/µl. Results are presented as medians with interquartile 
ranges (IQR), number and percentages of patients, incidence rates per 100,000 pys and 
hazard ratios (HRs) with 95% confidence intervals (CIs). Analyses were done using Stata 14 
(Stata Corporation, College Station, Texas, USA) and R (R Foundation, Vienna, Austria). 
 
Results 
Descriptive analyses 
The merged multiregional dataset included data on 408,395 HIV-positive adults. We excluded 
200,255 patients for reasons detailed in Supplementary figure S1. Excluded and included 
patients were similar with regard to gender (men 70% vs. 69%), risk group (MSM 33% vs. 
36%), age (median 35 vs. 37 years), and CD4 count at ART initiation (median 240 vs. 222 
cells/µl). 
We included data on 208,140 patients from 42 cohorts in 57 countries across the Asia-Pacific, 
South Africa, Europe, Latin, and North America (Figure 1). Median age at ART initiation was 
37.3 years (IQR 31.4-44.4) and similar across regions (Table 1). The percentage of men ranged 
from 37% in South Africa to 75% in North America. More men were MSM in Europe (54%), 
Latin America (57%), and North America (67%), though not in the Asia-Pacific (34%); data 
were not available for South Africa. Median CD4 cell count at ART initiation was <200 cells/µl 
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in the Asia-Pacific, South Africa, and Latin America, and >200 cells/µl in North America and 
Europe (Table 1). In South Africa and the Asia-Pacific, <5% of patients initiated ART before 
2004, but 39% in Europe and 63% in North America initiated ART between 1996 and 2003. 
Approximately half of North American and European patients initiated PI-based regimens, 
whereas 22% in Latin America, and <10% in South Africa and the Asia-Pacific received PI-based 
regimens. Median follow-up after ART initiation was >4 years in Europe, North, and Latin 
America, but shorter in the Asia-Pacific (2.7 years) and South Africa (2.0 years). 
Over 1,066,572 pys, 2,046 KS cases were diagnosed (Europe: 1,572; North America: 211, 
South Africa: 150, Latin America: 109; Supplementary table S1). Median time between ART 
initiation and KS diagnosis was 0.5 years (IQR 0.1-2.5). Median age at KS diagnosis ranged 
from 35 years in the Asia-Pacific to 43 years in North America. Median CD4 cell count at KS 
diagnosis was <100 cells/µl in the Asia-Pacific, Latin, and North America, and 180 cells/µl in 
South Africa and Europe.  
The raw KS incidence rate per 100,000 pys was highest in South Africa (280, 95% CI 238-328), 
followed by Latin America (244, 95% CI 203-295), North America (237, 95% CI 207-271), 
Europe (180, 95% CI 172-190), and the Asia-Pacific (52, 95% CI 19-137; Supplementary table 
S2). The raw KS incidence rates were especially high in patients with current CD4 counts <50 
cells/µl (ranging from 1,368 in South Africa to 2,950 in Latin America; Supplementary table 
S3); MSM in Europe, Latin, and North America (all >300), and South African men (371, 95% CI 
293-470; Supplementary table S4).  
Risk factors for incident KS  
The following statistical models include the regions Europe, South Africa, Latin, and North 
America. Crude KS incidence rates were highest immediately after ART initiation and declined 
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steeply thereafter in all population groups (Supplementary figures S2, S3). The effect of 
gender, age at ART initiation, and current CD4 cell count on KS risk varied across regions. In 
all regions, women had a lower risk of developing KS than men in crude and adjusted analyses, 
but the gender difference was less pronounced in South Africa (p-value for interaction <0.001; 
Table 2, Figure 2). In Europe, North, and Latin America, KS incidence rates were highest in 
MSM, followed by heterosexual men, and women in crude and adjusted analyses 
(Supplementary figure S4). After adjusting for current CD4 count, age at ART initiation, first-
line regimen, and calendar year of ART initiation, the KS risk was 53% higher in heterosexual 
men than women (adjusted HR [aHR] 1.53, 95% CI 1.28-1.83), and six times higher in MSM 
(aHR 5.95, 95% CI 5.09-6.96). There was no evidence that the effect of exposure group on KS 
risk differed across regions (p-value for interaction, 0.19). 
In all regions, KS risk was highest in persons with current CD4 cell counts <50 cells/µl. 
However, comparing patients with current CD4 cell counts ≥700 cells/µl to those with cell 
counts <50 cells/µl, KS risk was halved in South Africa (aHR 0.53, 95% CI 0.17-1.63), but 
reduced by ≥95% in the other regions (p-value for interaction <0.001; Figure 3). In Europe and 
North America, KS risk tended to increase with older age, whereas it decreased in Latin 
America and South Africa (p-value for interaction, 0.003; Table 2). There was no strong 
evidence that the effect of first-line regimen or calendar period of ART initiation varied across 
regions (Supplementary table S5). Patients who received PI-based first-line regimens had a 
slightly higher risk of developing KS than patients who received NNRTI-based regimens (aHR 
1.12. 95% CI 1.01-1.24). 
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Comparison of KS risk between regions 
In women, KS risk at two years after ART initiation was more than three times higher in South 
Africa than in Europe in crude analyses (HR 3.19, 95% CI 2.26-4.52) and almost five times 
higher in analyses adjusted for current CD4 count, age at ART initiation, first-line regimen, and 
calendar period of ART initiation (HR 4.56, 95% CI 2.73-7.62, Table 3). The adjusted KS risk 
tended to be lower in North, and Latin American women than in European women, but the 
effect was not statistically significant. In men, the crude risk of developing KS was highest in 
North America compared with Europe (HR 1.65, 95% CI 1.35-2.01), followed by South Africa 
(HR 1.44, 95% CI 1.03-2.00). In adjusted analyses, the HR for men declined to 0.75 (95% CI 
0.44-1.27) in North America, but it increased to 2.21 (95% CI 1.34-3.63) in South Africa. Both 
changes were mainly due to adjustment for current CD4 count. KS risk did not differ 
significantly between Latin American and European men in crude or adjusted analyses.  
We predicted KS incidence rates per 100,000 pys at two years after ART initiation for patients 
with current CD4 counts of 350-499 cells/µl who initiated NNRTI-based regimens between 
2008-2014 at the age of 40 years. Predicted KS incidence rates in women were 12 (95% CI 4-
36) in Latin America, 14 (95% CI 7-29) in North America, and 28 (95% CI 22-36) in Europe. In 
heterosexual men, KS incidence rates were 29 (95% CI 20-42) in Latin America, 35 (95% CI 27-
47) in North America, and 34 (95% CI 27-41) in Europe. In South Africa, KS incidence rates 
remained at 212 (95% CI 131-344) in men and 129 (95% CI 80-208) in women. Predicted KS 
incidence rates in MSM were 114 (95% CI 81-160) in Latin America, 131 (95% CI 109-157) in 
Europe, and 138 (95% CI 107-178) in North America (Supplementary table S6). 
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Sensitivity analysis 
Excluding the first three months of follow-up resulted in lower raw KS incidence rates 
(Supplementary table S7); other results remained similar (Supplementary tables S8-S10).  
 
Discussion 
After adjustment for HIV-related risk factors, HIV-positive men and women in South Africa 
had a higher risk of developing KS than their counterparts in Europe. In Europe, Latin, and 
North America, MSM had a higher KS risk than heterosexual men and women. In all regions, 
current CD4 cell count <50 cells/µl was a strong risk factor for incident KS. However, the clear 
trend towards lower KS risk with higher current CD4 counts seen in Europe, North, and Latin 
America was not observed in South Africa. 
This is the first study to directly compare KS risk across several continents in adults who 
initiated ART. We used the same inclusion criteria, definitions, and statistical methods across 
regions. However, comparability of incidence estimates might be impaired by regional and 
cohort-level differences in mode and completeness of KS ascertainment. We assumed that 
patients within regions were independent, which might have led us to overestimate the 
precision of regional KS risk comparisons. To reduce under-reporting of KS, data from South 
Africa were restricted to two urban cohorts that obtained additional KS data through record 
linkages with a cancer registry [2]. However, these South African data are not necessarily 
representative for the whole of South Africa, and it is unclear to what extent these results can 
be extrapolated to Southern Africa as a region.  We did not consider ART interruptions and, 
therefore, KS risk in patients continuously on ART might be lower than what we found in our 
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analysis for patients after ART initiation. Most patients from North America initiated ART 
before 2004 with NNRTI or PI-based regimens, whereas almost all patients in South Africa 
initiated NNRTI-based ART from 2004 onward. Temporal changes in ART effectiveness and 
HIV care in general might contribute to the observed regional differences in KS risk. HIV RNA 
measurements at ART initiation were missing for 30% of patients in Latin America and 78% in 
South Africa. Therefore, it was not possible to use HIV RNA measurements to assess ART 
response and treatment failure. Patient-level data on HHV-8 serostatus, immune 
reconstitution inflammatory syndrome (IRIS)-KS, and mode of KS ascertainment were 
generally not available. 
In our analyses, KS incidence rates were highest immediately after ART initiation, which is 
consistent with previous studies [4,5,10,19]. These peaks are partly explained by 
immunodeficiency that persisted after initiating ART, unmasking IRIS-KS [9,20], and possible 
misclassification of some prevalent KS as incident KS. However, when we excluded KS cases 
occurring within three months after ART initiation in sensitivity analyses, our results remained 
similar. The effect of age at ART initiation differed across regions with KS risk increasing with 
older age in North America and Europe, but decreasing in Latin America and South Africa. 
Most previous studies have shown no or only a weakly positive association between older age 
and KS risk in patients on ART [3–5,8,9,19,21]. The slightly increased KS risk in patients who 
received PI-based first-line regimens might be due to confounding by indication. 
Our study is one of the first to report KS incidence rates in HIV-positive adults in the Asia-
Pacific, a region where HHV-8 prevalence is generally low [22]. Compared to the other 
regions, we found KS risk to be much lower in the Asia-Pacific. KS incidence rates were higher 
in South African than in European men and women. Previous studies also tended to show 
12 
 
higher KS incidence rates in HIV-positive persons in sub-Saharan Africa [23,24], where HHV-8 
is endemic, than in Europe [9,21]. As in other studies, our analyses showed higher KS 
incidence rates in MSM than in heterosexual men [5,8,25], and higher KS risk in men than in 
women [19,25]. In South Africa, the gender difference in KS risk was smaller than in other 
regions. This pattern may reflect different HHV-8 risk profiles in HIV-positive men and women. 
In Europe, Latin, and North America, >50% of included men were MSM and, therefore, at high 
risk of HHV-8 coinfection, whereas women in these regions generally have lower HHV-8 
seroprevalence [7]. In sub-Saharan Africa where HHV-8 is endemic, both men and women are 
at high risk of HHV-8 coinfection [26]. Indirect effects of sex hormones on KS tumorigenesis 
[27] and gender differences in immune response might also contribute to the male 
predominance in KS risk.  
The high KS risk in South African compared with European women might be mainly explained 
by the higher HHV-8 prevalence in South African compared with European women. However, 
South African men also had a higher risk of developing KS than European men after 
adjustment for HIV-related factors. Besides differences in HHV-8 prevalence other factors like 
environmental exposures and malaria might play a role [28–30]. However, such co-factors for 
KS pathogenesis remain controversial. Our analyses also suggest that differences in access to 
HIV treatment and patient monitoring contribute to the regional differences in KS risk. For 
example, North American men had a higher risk of developing KS than European men, but 
after adjusting for current CD4 cell counts, the KS risk was similar.   
We and others found that high CD4 cell counts had a weaker protective effect in South Africa 
[3,19] than in other regions [5,8–10]. In line with other studies [24,31,32], this indicates that 
KS diagnosis and treatment will remain a relevant aspect of HIV care in Southern Africa, also 
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as access to ART is improving. Further research is needed to understand why patients with 
high current CD4 cell counts still develop KS, especially in Southern Africa but also in other 
regions of the world [33,34]. 
Conclusion 
Despite ART-related declines in KS incidence, men and women in South Africa and MSM 
remain at higher risk of developing KS than other HIV-positive persons, probably due to higher 
HHV-8 coinfection rates. While a vaccine against HHV-8 remains unavailable, early ART 
initiation and maintaining high CD4 cell counts are essential to reduce KS incidence in 
populations at high risk for HHV-8 coinfection.   
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Table 1: Characteristics of included adults at ART initiation. 
 Asia-Pacific South Africa Latin America North America Europe 
 N (%) N (%) N (%) N (%) N (%) 
All adults 2,641 (100%) 21,421 (100%) 8,454 (100%) 16,742 (100%) 158,882 (100%) 
Median follow-up 
time (IQR) [years] 2.7 (1.7-3.9) 2.0 (0.8-4.0) 4.6 (1.9-8.1) 4.2 (1.7-8.5) 4.4 (1.8-8.4) 
Gender      
   Women       816  (31%)       13,554  (63%)       2,264  (27%)        4,218  (25%)     44,198  (28%) 
   Men       1825  (69%)        7,867  (37%)       6,190  (73%)      12,524  (75%)     114,684  (72%) 
Median age at 
ART initiation 
(IQR) [years] 
  36.3  
(30.5- 43.1) 
  36.4  
(31.0-42.7) 
  35.6  
(29.7-42.9) 
  39.6  
(33.8-46.1) 
37.3 
(31.4-44.5) 
Age at ART 
initiation [years] 
     
   16-25       233   (9%)          1,719   (8%)           993  (12%)           923   (6%)     13,186   (8%) 
   26-35      1053  (40%)          8,549  (40%)        3,372  (40%)          4,770  (28%)     57,333  (36%) 
   36-45       871  (33%)          7,689  (36%)        2,568  (30%)          6,825  (41%)     54,749  (34%) 
   46-55       355  (13%)          2,851  (13%)        1,111  (13%)          3,305  (20%)     23,460  (15%) 
   ≥ 56       129   (5%)           613   (3%)           410   (5%)           919   (5%)     10,154   (6%) 
Mode of infection      
   MSM       616  (23%)     NR        3,543  (42%)          8,419  (50%)     62,314  (39%) 
   PWID       164   (6%)     NR           169   (2%)          1,794  (11%)     17,241  (11%) 
   Heterosexual      1678  (64%)         17,965  (84%)        3,671  (43%)          4,965  (30%)     65,445  (41%) 
   Other       175   (7%)             9   (<1%)            91   (1%)           258   (2%)     3,520   (2%) 
   Missing         8   (<1%)          3,447  (16%)           980  (12%)          1,306   (8%)     10,362   (7%) 
First line ART 
regimen 
     
   NNRTI-based      2375  (90%)         20,267  (95%)        6,361  (75%)          6,167  (37%)     66,569  (42%) 
   PI-based       229   (9%)          1,107   (5%)        1,891  (22%)          9,044  (54%)     80,995  (51%) 
   Other ART        37   (1%)            47   (<1%)           202   (2%)          1,531   (9%)     11,318   (7%) 
Year of ART 
initiation 
     
   1996-1998         0   (0%)             0   (0%)           107   (1%)          5,332  (32%)     18,771  (12%) 
   1999-2003       100   (4%)            99   (<1%)        1,926  (23%)          5,167  (31%)     43,004  (27%) 
   2004-2007       510  (19%)         10,365  (48%)        2,786  (33%)          4,055  (24%)     39,388  (25%) 
   2008-2014      2,031  (77%)         10,957  (51%)        3,635  (43%)          2,188  (13%)     57,719  (36%) 
CDC stage at ART 
initiation 
     
   A/B      1,225  (46%)         16,561  (77%)        3,850  (46%)         11,920  (71%)     122,365  (77%) 
   C       921  (35%)           746   (3%)        1,183  (14%)          2,536  (15%)     19,708  (12%) 
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ART, antiretroviral therapy; CDC, Centers for Disease Control and Prevention; IQR, interquartile 
range; KS, Kaposi sarcoma; MSM, men who have sex with men; NNRTI, non-nucleoside reverse-
transcriptase inhibitor; NR, not reported; PI, protease-inhibitor; PWID, persons who inject drugs; 
RNA, ribonucleic acid.  
 
 
  
   Missing       495  (19%)          4,114  (19%)        3,421  (40%)          2,286  (14%)     16,809  (11%) 
Median CD4 cell 
count  at ART 
initiation (IQR) 
[cells/µl] 
137  
(43-234) 
 107  
(43-176) 
 165  
(61-273) 
 233  
(93-378) 
250 
(128-369) 
CD4 cell count at 
ART initiation 
[cells/µl] 
     
   < 50        680  (26%)          5,461  (25%)        1,509  (18%)          2,620  (16%)     17,691  (11%) 
   50-99       327  (12%)          3,915  (18%)        1,031  (12%)          1,318   (8%)     11,749   (7%) 
   100-199       604  (23%)          7,178  (34%)        1,649  (20%)          2,620  (16%)     25,890  (16%) 
   200-349       736  (28%)          2,589  (12%)        2,145  (25%)          4,205  (25%)     48,185  (30%) 
   350-499        95   (4%)           395   (2%)           584   (7%)          2,340  (14%)     23,895  (15%) 
   500-699        16   (1%)           188   (1%)           204   (2%)          1,343   (8%)     11,225   (7%) 
   ≥ 700         6   (<1%)            81   (<1%)            81   (1%)           694   (4%)     5,498   (3%) 
   Missing       177   (7%)          1,614   (8%)        1,251  (15%)          1,602  (10%)     14,749   (9%) 
Median HIV RNA  
at ART initiation 
(IQR) [log10 
copies/ml] 
   5.0  
(4.5-5.4) 
   4.5  
(2.7-5.3) 
   4.9   
(4.3-5.4) 
   4.5   
(3.5-5.2) 
4.8 
(4.1-5.3) 
HIV RNA at ART 
initiation  
[log10 copies/ml] 
     
   < 2.7        43   (2%)          1,192   (6%)           278   (3%)          2,485  (15%)     13,057   (8%) 
   2.7-3.9       201   (8%)           589   (3%)           699   (8%)          2,392  (14%)     18,352  (12%) 
   4.0-4.9       760  (29%)          1,306   (6%)        2,273  (27%)          5,132  (31%)     50,850  (32%) 
   ≥ 5.0       1,044  (40%)          1,633   (8%)        2,673  (32%)          4,499  (27%)     54,417  (34%) 
   Missing        593   (22%)         16,701  (78%)        2,531  (30%)          2,234  (13%)     22,206  (14%) 
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Table 2: Regional risk factors for incident KS in adults who initiated ART. 
 South Africa Latin America North America Europe p-value for  
 HR* (95% CI) HR* (95% CI) HR* (95% CI) HR* (95% CI) interaction** 
Gender     <0.001 
   Male 1.00 1.00 1.00 1.00  
   Female 0.61 (0.44 - 0.85) 0.19 (0.09 - 0.41) 0.20 (0.12 - 0.34) 0.29 (0.25 - 0.35)  
Age at ART initiation      0.003 
   Per decade increase 0.76 (0.62 - 0.93) 0.88 (0.72 - 1.09) 1.17 (1.01 - 1.36) 1.04 (0.99 - 1.09)  
* Adjusted for current CD4 cell count and its interaction with region, gender and its interaction with region, age and its interaction with region, calendar 
year of ART start, and first-line ART regimen. 
** Derived from likelihood ratio test comparing the main adjusted model with the model without interaction of a specific variable with region. 
ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio, KS, Kaposi sarcoma.
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Table 3:  Comparison of KS risk between different regions and Europe: Crude and adjusted HRs for 
developing KS at 2 years after ART initiation in women and men. 
 
* For HIV-positive patients with a current CD4 cell count of 350-499 cells/µl who initiated an NNRTI-
based regimen between 2008-2014 at the age of 40 years. 
ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio. 
 
 
 Women Men 
 Crude HR  
(95% CI) 
Adjusted HR*  
(95% CI) 
Crude HR  
(95% CI) 
Adjusted HR*  
(95% CI) 
Region     
   Europe 1.00 1.00 1.00 1.00 
   North America 1.16 (0.68 - 2.00) 
 
0.50 (0.24 - 1.04) 
 
1.65 (1.35 - 2.01) 
 
0.75 (0.44 - 1.27) 
    Latin America 0.73 (0.33 - 1.63) 
 
0.43 (0.14 - 1.27) 
 
1.17 (0.84 - 1.64) 
 
0.65 (0.29 - 1.48) 
    South Africa 3.19 (2.26 - 4.52) 
 
4.56 (2.73 - 7.62) 
 
1.44 (1.03 - 2.00) 
 
2.21 (1.34 - 3.63) 
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Figure 1: Map of countries contributing patient data to the descriptive analyses. 
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Figure 2: KS incidence rates by time since ART initiation in men and women predicted from 
the crude model with gender and its interaction with region (Panel A), and predicted from 
the main adjusted model for men and women with a current CD4 cell count of 350-499 
cells/µl who initiated an NNRTI-based first-line ART regimen between 2008-2014 at the age 
of 40 years (Panel B). ART, antiretroviral therapy; KS, Kaposi sarcoma; NNRTI, non-
nucleoside reverse transcriptase inhibitor; pys, person-years. 
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Figure 3: Regional effects of current CD4 cell counts on the risk of developing Kaposi 
sarcoma in adults who initiated antiretroviral therapy. 
 
* Adjusted for gender and its interaction with region, age and its interaction with region, calendar year of ART 
start, and first-line ART regimen. 
** Derived from likelihood ratio test comparing the main adjusted model with the model without interaction 
of a specific variable with region. 
ART, antiretroviral therapy; CI, confidence interval; KS, Kaposi sarcoma
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Supplementary box S1: Collection and merging of cohort data. 
We analyzed longitudinal routine clinical care data of HIV-positive patients within the framework of 
the International epidemiology Databases to Evaluate AIDS (IeDEA) and the Collaboration of 
Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. COHERE in EuroCoord 
contributed data from 24 cohorts covering 36 countries through the 2014 merger. Cohorts 
participating in IeDEA and COHERE in EuroCoord routinely collect clinical, demographic, laboratory, 
and treatment data during enrollment and follow-up visits. Patient data are then de-identified and 
transferred to regional data centres for merging. Through standard procedures for data request we 
obtained regional data sets in their respective standard data exchange formats from the data centers 
in 2014. We performed quality checks, harmonized the regional data sets by renaming variables and 
creating new variables based on available information, and eventually combined them into one 
multiregional data set for use in this analysis.     
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Supplementary figure S1: Identification of study population for analysis. The flow diagram shows the 
number of included and excluded patients.
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Supplementary figure S2: KS incidence rates by time since ART initiation in men and women 
predicted from the crude model with gender and its interaction with region.   
 
ART, antiretroviral therapy; KS, Kaposi sarcoma; pys, person-years. 
 
 
Supplementary figure S3: KS incidence rates by time since ART initiation in MSM, heterosexual men 
and women predicted from the crude model with exposure group. 
 
ART, antiretroviral therapy; KS, Kaposi sarcoma; MSM, men who have sex with men; pys, person-
years. 
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Supplementary Figure S4: KS incidence rates by time since ART initiation in MSM, heterosexual men, 
and women predicted from the crude model with exposure group (Panel A), and predicted from the 
main adjusted model for MSM, heterosexual men, and women with a current CD4 cell count of 350-
499 cells/µl who initiated an NNRTI-based first-line ART regimen between 2008-2014 at the age of 40 
years (Panel B). ART, antiretroviral therapy; KS, Kaposi sarcoma; MSM, men who have sex with men; 
NNRTI, non-nucleoside reverse transcriptase inhibitor; pys, person-years. 
Panel A 
 
Panel B 
 
ART, antiretroviral therapy; KS, Kaposi sarcoma; MSM, men who have sex with men; NNRTI, non-
nucleoside reverse transcriptase inhibitor; py, person-years.
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Supplementary table S1: Characteristics of adults with incident KS. With only four incident KS cases, 
data for the Asia-Pacific region are not shown. 
 
 South Africa Latin America North America Europe 
 N (%) N (%) N (%) N (%) 
All KS cases 150 (100%) 109 (100%) 211 (100%) 1572 (100%) 
Median time to KS 
diagnosis (IQR) [years]    0.4 (0.2-1.4)   0.3 (0.1-1.3)    0.8 (0.2-3.8)    0.5 (0.1-2.6) 
Gender     
   Women       81  (54%)             7   (6%)           15   (7%)            160  (10%)     
   Men        69  (46%)           102  (94%)          196  (93%)           1412  (90%)     
Median age at KS 
diagnosis (IQR) [years] 
36.0 
(30.2-40.9) 
36.7  
(31.4-41.7) 
42.9 
(37.6-48.7) 
40.2 
(34.1-47.8) 
Mode of infection     
   MSM NR            71  (65%)          158  (75%)           1037  (66%)     
   PWID NR             0   (0%)            7   (3%)             61   (4%)     
   Heterosexual      130  (87%)            26  (24%)           31  (15%)            367  (23%)     
   Other        0   (0%)             1   (1%)            3   (1%)             20   (1%)     
   Missing       20  (13%)            11  (10%)           12   (6%)             87   (6%)     
First line ART regimen     
   NNRTI-based      144  (96%)            76  (70%)           61  (29%)            532  (34%)     
   PI-based        6   (4%)            31  (28%)          129  (61%)            934  (59%)     
   Other ART        0   (0%)             2   (2%)           21  (10%)            106   (7%)     
Year of ART initiation     
   1996-1998        0   (0%)             2   (2%)           85  (40%)            336  (21%)     
   1999-2003        0   (0%)            30  (28%)           71  (34%)            548  (35%)     
   2004-2007       88  (59%)            31  (28%)           42  (20%)            344  (22%)     
   2008-2014       62  (41%)            46  (42%)           13   (6%)            344  (22%)     
CDC stage at ART 
initiation 
   
 
   A/B      107  (71%)            33  (30%)          130  (62%)           1103 (70%)     
   C        5   (3%)            36  (33%)           59  (28%)            418 (27%)     
   Missing       38  (25%)            40  (37%)           22  (10%)             51   (3%)     
Median CD4 cell count  at 
KS diagnosis (IQR) 
[cells/µl] 
 180 
 (50-320) 
 77  
(29-139) 
  87 
 (20-282) 
 180 
 (60-348) 
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ART, antiretroviral therapy; CDC, Centers for Disease Control and Prevention; IQR, interquartile 
range; KS, Kaposi sarcoma; MSM, men who have sex with men; NNRTI, non-nucleoside reverse-
transcriptase inhibitors; NR, not reported; PI, protease-inhibitors; PWID, persons who inject drugs; 
RNA, ribonucleic acid.  
 
 
  
CD4 cell count at KS 
diagnosis [cells/µl] 
   
 
   < 50        33  (22%)            32  (29%)           73  (35%)            292  (19%)     
   50-99       12   (8%)            19  (17%)           23  (11%)            179  (11%)     
   100-199       33  (22%)            25  (23%)           30  (14%)            256  (16%)     
   200-349       23  (15%)             8   (7%)           30  (14%)            301  (19%)     
   350-499       21  (14%)             6   (6%)           14   (7%)            189  (12%)     
   500-699        8   (5%)             1   (1%)           10   (5%)            103   (7%)     
   ≥ 700        4   (3%)             0   (0%)            6   (3%)             49   (3%)     
   Missing       16  (11%)            18  (17%)           25  (12%)            203  (13%)     
Median HIV RNA at KS 
diagnosis (IQR) [log10 
copies/ml] 
   1.7   
(1.7-2.2) 
  4.4   
(1.9-5.0) 
   3.8   
(2.3-5.1) 
   3.4   
(2.0-5.2) 
HIV RNA at KS diagnosis 
[log10 copies/ml] 
   
 
   < 2.7       63  (42%)            25  (23%)           70  (33%)            503  (32%)     
   2.7-3.9        4   (3%)             9   (8%)           25  (12%)            189  (12%)     
   4.0-4.9        5   (3%)            23  (21%)           30  (14%)            182  (12%)     
   ≥ 5.0        4   (3%)            20  (18%)           51  (24%)            385  (24%)     
   Missing       74  (49%)            32  (29%)           35  (17%)            313  (20%)     
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Supplementary table S2: Raw overall KS incidence rates per 100,000 pys by region. 
 
 
 
 
 
CI, confidence interval; KS, Kaposi sarcoma; N, number; pys, person-years.
 Patients  
(N) 
Person- 
years  
Cases 
 (N) 
Incidence rate  
(95% CI) 
Region     
Asia-Pacific 2,641 
 
7,757 
 
4 52 (19-137) 
 
South Africa 21,421 
 
53,648 
 
150 280 (238-328) 
 
Latin America 8,454 
 
44,603 
 
109 244 (203-295) 
 
North America 16,742 
 
88,952 
 
211 237 (207-271) 
 
Europe 158,882 
 
871,612 
fds 
1,572 180 (172-190) 
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Supplementary table S3: Raw KS incidence rates per 100,000 pys and 95% CIs, stratified by region and current CD4 cell count. With only four incident KS cases, 
data for the Asia-Pacific region are not shown. 
 
ART, antiretroviral therapy; CDC, Centers for Disease Control and Prevention; IQR, interquartile range; KS, Kaposi sarcoma; MSM, men who have sex with men; 
NNRTI, non-nucleoside reverse-transcriptase inhibitors; PI, protease-inhibitors; pys, person-years.  
 South Africa Latin America North America Europe 
 pys 
Cases 
(N) 
Incidence rate 
(95% CI) 
pys 
Cases 
(N) 
Incidence rate 
(95% CI) 
pys 
Cases 
(N) 
Incidence rate 
(95% CI) 
pys 
Cases 
(N) 
Incidence rate 
(95% CI) 
Current CD4 cell 
count [cells/µl] 
            
   < 50 2,631 36 
1368  
(987 - 1897) 
1,356 40 
2950  
(2164 - 4022) 
4,002 81 
2024  
(1628 - 2516) 
14,272 320 
2242  
(2010 - 2502) 
   50-99 3,183 13 
408  
(237 - 703) 
1,607 22 
1369  
(901 - 2079) 
3,439 24 
698  
(468 - 1041) 
18,257 195 
1068  
(928 - 1229) 
   100-199 10,373 39 
376  
(275 - 515) 
5,258 27 
514  
(352 - 749) 
9,765 37 
379  
(275 - 523) 
64,653 290 
449  
(400 - 503) 
   200-349 15,975 25 
156  
(106 - 232) 
10,898 10 
92  
(49 - 171) 
20,021 36 
180 
 (130 - 249) 
167,460 345 
206  
(185 - 229) 
   350-499 11,299 22 
195  
(128 - 296) 
10,111 6 
59  
(27 - 132) 
19,529 15 
77  
(46 - 127) 
204,687 232 
113 
 (100 - 129) 
   500-699 6,955 11 
158  
(88 - 286) 
8,603 3 
35  
(11 - 108) 
17,834 11 
62  
(34 - 111) 
209,193 122 
58  
(49 - 70) 
   ≥ 700 2,778 4 
144  
(54 - 384) 
6,127 1 
16  
(2 - 116) 
14,296 7 
49  
(23 - 103) 
183,050 68 
37  
(29 - 47) 
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Supplementary table S4: Raw KS incidence rates per 100,000 pys and 95% CIs, stratified by region 
and risk factor. With only four incident KS cases, data for the Asia-Pacific region are not shown. 
ART, antiretroviral therapy; CDC, Centers for Disease Control and Prevention; IQR, interquartile 
range; KS, Kaposi sarcoma; MSM, men who have sex with men; NNRTI, non-nucleoside reverse-
transcriptase inhibitors; PI, protease-inhibitors; pys, person-years.  
  
 South Africa Latin America North America Europe 
Gender and sexual 
orientation 
    
   Women 231 (186-287) 56 (27-117) 58 (35-97) 65 (55-76) 
   Men  371 (293-470) 318 (262-387) 310 (269-356) 226 (215-238) 
      Heterosexual men - 216 (142-328) 167 (114-243) 119 (107-133) 
      MSM - 388 (307-489) 361 (309-422) 311 (292-330) 
Age at ART initiation [years]     
   16-25 303 (176-523) 248 (141-438) 95 (36-253) 115 (93-143) 
   26-35 323 (257-406) 268 (202-355) 220 (170-285) 167 (154-181) 
   36-45 255 (192-338) 256 (185-355) 247 (202-302) 177 (163-193) 
   46-55 209 (124-353) 138 (69-276) 278 (208-373) 236 (210-266) 
   ≥ 56 162 (40-646) 251 (104-602) 241 (130-449) 254 (213-304) 
First line ART regimen     
   NNRTI-based 288 (244-339) 231 (185-290) 232 (180-298) 159 (146-173) 
   PI-based 176 (79-393) 293 (206-417) 236 (198-280) 199 (186-212) 
   Other ART - 168 (42-672) 268 (175-411) 160 (132-193) 
Year of ART initiation     
   1996-1998 - 155 (39-619) 196 (159-243) 173 (156-193) 
   1999-2003 - 178 (125-255) 235 (186-296) 157 (144-170) 
   2004-2007 233 (189-287) 176 (124-250) 321 (237-434) 168 (151-187) 
   2008-2014 404 (315-518) 521 (390-695) 549 (319-946) 279 (251-311) 
CDC stage at ART initiation     
   A/B 249 (206-301) 168 (119-236) 203 (171-241) 169 (159-179) 
   C 332 (138-797) 522 (376-723) 470 (364-607) 356 (323-392) 
   Missing - - - - 
49 
 
Supplementary table S5: Effect of calendar period of ART initiation and first-line ART regimen on the 
risk of developing KS.  
 
Crude HR 
(95% CI) 
Adjusted HR* 
(95% CI) 
p-value for 
interaction** 
Calendar period of ART initiation   0.046 
    2008-2014 1.00 1.00  
    2004-2007 1.04 (0.92 - 1.18) 0.87 (0.76 - 0.99)  
    1999-2003 1.30 (1.15 - 1.48) 0.94 (0.83 - 1.07)  
    1996-1998 1.60 (1.39 - 1.85) 1.03 (0.89 - 1.20)  
First-line ART regimen   0.71 
    NNRTI-based 1.00 1.00  
    PI-based 1.34 (1.22 - 1.47) 1.12 (1.01 - 1.24)  
    Other ART 1.12 (0.92 - 1.35) 1.10 (0.91 - 1.33)  
 
* Adjusted for calendar year of ART start, first-line ART regimen, current CD4 cell count and its 
interaction with region, gender and its interaction with region, and age and its interaction with 
region. 
** Derived from likelihood ratio test comparing the main adjusted model with the model without 
interaction of a specific variable with region. 
ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratios; KS, Kaposi sarcoma; NNRTI, 
non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.  
50 
 
Supplementary table S6: KS incidence rates per 100,000 pys and 95% CIs at 2 years after ART 
initiation predicted for patients with a current CD4 cell count of 350-499 cells/µl who initiated an 
NNRTI-based regimen between 2008-2014 at the age of 40 years from the adjusted models with 
gender (upper two rows) or exposure group (lower two rows). 
*Incidence rate (IR) per 100,000 person-years and 95% confidence intervals (CI) 
 
 
  
 South Africa Latin America North America Europe 
 IR (95% CI)* IR (95% CI)* IR (95% CI)* IR (95% CI)* 
Gender and exposure group 
orientation 
    
   Women 129 (80-208) 
 
12 (4-36) 
 
14 (7-29) 
 
28 (22-36) 
 
   Men  212 (131-344) 
 
63 (28-142) 
 
72 (42-121) 
 
96 (80-115) 
       Heterosexual men - 
29 (20-42) 
 
35 (27-47) 
 
34 (27-41) 
       MSM - 
114 (81-160) 
 
138 (107-178) 
 
131 (109-157) 
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Supplementary table S7: Raw overall KS incidence rates per 100,000 pys by region, excluding the first 
three months after ART initiation in a sensitivity analysis. 
 
 
 
 
 
CI, confidence interval; KS, Kaposi sarcoma; N, number; pys, person-years. 
 
  
 Patients  
(N) 
Person- 
years  
Cases 
 (N) 
Incidence rate  
(95% CI) 
Region     
Asia-Pacific 2,505 7,115 3 39 (13 - 120) 
 South Africa 19,050 48,608 94 176 (144 - 216) 
 Latin America 8,075 42,536 61 137 (107 - 176) 
 North America 16,253 84,812 143 161 (137 – 190) 
 Europe 151,742 832,736 945 109 (102 - 116) 
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Supplementary table S8: Comparison of KS risk between different regions and Europe, crude and 
adjusted HRs for being diagnosed with KS at 2 years after ART initiation in women and men from a 
sensitivity analysis excluding the first three months after ART initiation. 
 
* Predictions for HIV-positive patients with a current CD4 cell count of 350-499 cells/µl who initiated 
an NNRTI-based regimen between 2008-2014 at the age of 40 years. 
ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio.
 Women Men 
 Crude HR  
(95% CI) 
Adjusted HR*  
(95% CI) 
Crude HR  
(95% CI) 
Adjusted HR*  
(95% CI) 
Region     
   Europe 1.00 1.00 1.00 1.00 
   North America 1.09 (0.60 - 1.98) 
 
0.56 (0.26 - 1.23) 
 
1.58 (1.29 - 1.93) 
 
0.90 (0.52 - 1.54) 
    Latin America 0.47 (0.15 - 1.50) 
 
0.25 (0.06 - 1.05) 
 
1.18 (0.86 - 1.62) 
 
0.62 (0.25 - 1.54) 
    South Africa 2.51 (1.70 - 3.70) 
 
3.92 (2.23 - 6.88) 
 
1.50 (1.05 - 2.15) 
 
2.61 (1.53 - 4.45) 
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Supplementary table S9: Regional risk factors for incident KS in adults who initiated ART from a sensitivity analysis excluding the first three months after ART 
initiation. 
 South Africa Latin America North America Europe 
 HR* (95% CI) HR* (95% CI) HR* (95% CI) HR* (95% CI) 
Gender     
   Male 1.00 1.00 1.00 1.00 
   Female 0.51 (0.34 - 0.78) 0.14 (0.04 - 0.44) 0.21 (0.12 - 0.39) 0.34 (0.28 - 0.42) 
Current CD4 cell count [cells/µl]     
   < 50  1.00 1.00 1.00 1.00 
   50-99 0.26 (0.08 - 0.82) 0.41 (0.19 - 0.88) 0.23 (0.12 - 0.44) 0.42 (0.33 - 0.55) 
   100-199 0.48 (0.23 - 1.01) 0.23 (0.12 - 0.45) 0.17 (0.11 - 0.28) 0.23 (0.18 - 0.28) 
   200-349 0.32 (0.14 - 0.69) 0.04 (0.02 - 0.11) 0.10 (0.06 - 0.15) 0.13 (0.11 - 0.16) 
   350-499 0.61 (0.27 - 1.37) 0.04 (0.01 - 0.11) 0.06 (0.03 - 0.10) 0.09 (0.07 - 0.11) 
   500-699 0.63 (0.25 - 1.62) 0.03 (0.01 - 0.10) 0.03 (0.02 - 0.07) 0.05 (0.04 - 0.07) 
   ≥ 700 0.68 (0.20 - 2.36) - 0.04 (0.02 - 0.09) 0.04 (0.03 - 0.05) 
Age at ART initiation      
   Per decade increase 0.79 (0.61 - 1.02) 0.76 (0.57 - 1.02) 1.11 (0.92 - 1.35) 1.01 (0.95 - 1.08) 
* Adjusted for current CD4 cell count and its interaction with region, gender and its interaction with region, age and its interaction with region, calendar year of 
ART start, and first-line ART regimen. 
ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio, KS, Kaposi sarcoma.
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Supplementary table S10: KS incidence rates per 100,000 pys and 95% CIs at 2 years after ART 
initiation from a sensitivity analysis excluding the first three months on ART; predicted for patients 
with a current CD4 cell count of 350-499 cells/µl who initiated an NNRTI-based regimen between 
2008-2014 at the age of 40 years from the adjusted models with gender (upper two rows) or 
exposure group (lower two rows).  
*Incidence rate (IR) per 100,000 person-years and 95% confidence intervals (CI) 
ART, antiretroviral therapy; MSM, men who have sex with men; NNRTI, non-nucleoside reverse 
transcriptase inhibitor. 
 
 
 South Africa Latin America North America Europe 
 IR (95% CI)* IR (95% CI)* IR (95% CI)* IR (95% CI)* 
Gender and exposure group 
orientation 
    
   Women 118 (69-199) 
 
7 (2-31) 
 
17 (8-36) 
 
30 (23-40) 
 
   Men  229 (136-387) 
 
55 (22-135) 
 
79 (46-136) 
 
88 (70-110) 
       Heterosexual men - 
30 (20-44) 
 
33 (23-45) 
 
36 (27-46) 
       MSM - 
105 (73-151) 
 
115 (85-155) 
 
126 (100-158) 
 
